TW202243691A - 使用抗ｔｉｇｉｔ抗體與抗ｐｄ１抗體組合治療癌症之方法 - Google Patents

使用抗ｔｉｇｉｔ抗體與抗ｐｄ１抗體組合治療癌症之方法 Download PDF

Info

Publication number
TW202243691A
TW202243691A TW111102344A TW111102344A TW202243691A TW 202243691 A TW202243691 A TW 202243691A TW 111102344 A TW111102344 A TW 111102344A TW 111102344 A TW111102344 A TW 111102344A TW 202243691 A TW202243691 A TW 202243691A
Authority
TW
Taiwan
Prior art keywords
cancer
antibody
seq
tigit
ser
Prior art date
Application number
TW111102344A
Other languages
English (en)
Chinese (zh)
Inventor
張彤
薛柳
劉琦
魏旻
康 李
左云霞
Original Assignee
英屬開曼群島商百濟神州有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英屬開曼群島商百濟神州有限公司 filed Critical 英屬開曼群島商百濟神州有限公司
Publication of TW202243691A publication Critical patent/TW202243691A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111102344A 2021-01-21 2022-01-20 使用抗ｔｉｇｉｔ抗體與抗ｐｄ１抗體組合治療癌症之方法 TW202243691A (zh)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
WOPCT/CN2021/073083 2021-01-21
CN2021073083 2021-01-21
WOPCT/CN2021/073308 2021-01-22
CN2021073308 2021-01-22
CN2021074141 2021-01-28
WOPCT/CN2021/074141 2021-01-28
WOPCT/CN2021/074644 2021-02-01
CN2021074644 2021-02-01
WOPCT/CN2021/075310 2021-02-04
CN2021075310 2021-02-04
CN2021091822 2021-05-05
WOPCT/CN2021/091822 2021-05-05
WOPCT/CN2021/109322 2021-07-29
CN2021109322 2021-07-29

Publications (1)

Publication Number Publication Date
TW202243691A true TW202243691A (zh) 2022-11-16

Family

ID=82548518

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111102344A TW202243691A (zh) 2021-01-21 2022-01-20 使用抗ｔｉｇｉｔ抗體與抗ｐｄ１抗體組合治療癌症之方法

Country Status (13)

Country Link
US (1) US20230391883A1 (OSRAM)
EP (1) EP4281189A4 (OSRAM)
JP (1) JP2024504331A (OSRAM)
KR (1) KR20230158464A (OSRAM)
CN (1) CN117177770A (OSRAM)
AU (1) AU2022211109A1 (OSRAM)
BR (1) BR112023014582A2 (OSRAM)
CO (1) CO2023009626A2 (OSRAM)
IL (1) IL304600A (OSRAM)
MX (1) MX2023008597A (OSRAM)
PE (1) PE20240659A1 (OSRAM)
TW (1) TW202243691A (OSRAM)
WO (1) WO2022156726A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115746144B (zh) * 2022-09-02 2026-01-02 安徽瀚海博兴生物技术有限公司 抗tigit-pd1双特异性抗体及其应用
CN121219319A (zh) * 2023-06-27 2025-12-26 正大天晴药业集团股份有限公司 抗tigit抗体及其应用
CN121003695A (zh) * 2024-05-24 2025-11-25 百奥泰生物制药股份有限公司 抗tigit抗体和抗pd-1抗体联合治疗肿瘤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI888366B (zh) * 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
TWI816729B (zh) * 2017-12-30 2023-10-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
EP3746119A4 (en) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
MX2020008882A (es) * 2018-02-26 2021-01-08 Genentech Inc Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
CN108840932B (zh) * 2018-04-28 2022-03-29 中国科学院微生物研究所 一种pd-1特异性抗体及其抗肿瘤应用
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
CN111744013B (zh) * 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN112618577B (zh) * 2020-12-15 2023-07-25 深圳君拓生物科技有限公司 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用

Also Published As

Publication number Publication date
IL304600A (en) 2023-09-01
CN117177770A (zh) 2023-12-05
EP4281189A4 (en) 2025-01-08
JP2024504331A (ja) 2024-01-31
BR112023014582A2 (pt) 2023-09-26
AU2022211109A1 (en) 2023-09-07
EP4281189A1 (en) 2023-11-29
MX2023008597A (es) 2023-08-10
PE20240659A1 (es) 2024-04-04
KR20230158464A (ko) 2023-11-20
CO2023009626A2 (es) 2023-09-08
WO2022156726A1 (en) 2022-07-28
US20230391883A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
CN112566935B (zh) 抗ox40抗体和使用方法
EP3328407A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
WO2022156726A1 (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies
WO2021098774A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
WO2021098757A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
CN114728063B (zh) 用抗ox40抗体和多重激酶抑制剂治疗癌症
CA3205839A1 (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
TW202304984A (zh) 抗人類ｃｘｃｒ５抗體及其用途
CN114729047A (zh) 使用抗ox40抗体与化学治疗剂组合治疗癌症的方法
HK40103924A (zh) 使用抗tigit抗体与抗pd1抗体组合治疗癌症的方法
HK40074321A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
CN119698295A (zh) 使用抗tigit抗体的癌症治疗方法
HK40076665A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
HK40076664A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
HK40089230A (zh) 药物组合物及用途
EA047697B1 (ru) Способы лечения рака с использованием антител к ox40 в комбинации с антителами к pd1 или к pdl1
HK40050839A (en) Anti-ox40 antibodies and methods of use